UA128045U - METHOD OF FORECASTING OSTEOARTHrosis DEVELOPMENT - Google Patents

Abstract

A method for predicting the development of osteoarthritis includes clinical examination, radiography. Determine in serum the polymorphism of the gene methylenetetrahydrofolate reductase (MTHFR C677T), the content of glycosaminoglycans (GAG), C-reactive protein (PSA). With homozygous carrier 677-TT and levels of GAG> 28 μmol / l, PSA> 6 mg / l predict the development of osteoarthritis.

Description

The proposed useful model The method of predicting the development of osteoarthritis belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (Okorokov

A.N. Diagnosis of diseases of internal organs. - Vol. 2. - M., 2001. - P. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to clinical examination and radiography, the polymorphism of the methylenetetrahydrofolate reductase gene (MTNEV C677T), the content of glycosaminoglycans (GAG), C-reactive protein (CRP) is determined in the patient's blood serum, and in case of homozygous carrier 677-

TT, HAG content »28 μmol/l, PSA »6 mg/l predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, an X-ray is taken, and the MTNEV C677T gene polymorphism is determined. The GAG content is determined by the immunoenzymatic method,

SRP With homozygous carrier 677-TT, GAG levels of 228 μmol/l, SRP »6 mg/l predict the development of osteoarthritis.

A specific example of using the method

Patient O., 62 years old, was admitted to the clinic due to pain in the right hip joint. Examined, x-ray taken. No signs of osteoarthritis were found. Polymorphism of MTNEV C677T gene was determined in blood serum. The content of HAG and SRP was determined by immunoenzymatic method. Homozygous carrier 677-1T was established. GAG levels - 37 μmol/l,

SRP - 13 mg/l. The development of osteoarthritis was diagnosed. After 12 months, X-rays revealed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Coo)

Claims (1)

USEFUL MODEL FORMULA A method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that the polymorphism of the methylenetetrahydrofolate reductase gene (MTNEVK C677T), the content of glycosaminoglycans (GAG), C-reactive protein (CRP), in homozygous carriers are determined in the blood serum 67 7-11 and GAG levels of 228 μmol/l, SRP of 26 mg/l predict the development of osteoarthritis.